RT期刊文章SR电子T1多民族人口主要扭力肌张力障碍的发生率(S53.001)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP S53.001 OP S53.001 VO 80是7补充A1卡罗首页琳·坦纳A1凯萨琳Albers A1塞缪尔高盛A1 Jeffrey Klingman A1 Raymond Lo A1康尼马拉A1紫水晶Leimpeter A1罗宾Fross A1 Zhuqin顾A1罗宾Smit A1 Annelie de Kleijn A1恩典Bhudhikanok A1劳里Ozelius A1苏珊Bressman A1瑞秋Saunders-Pullman A1辛西娅·考米拉A1 Lorene Nelson A1斯蒂芬·范Eeden年2013 UL //www.ez-admanager.com/content/80/7_Supplement/S53.001.abstract AB目的:确定主要扭力肌张力障碍的发病率(输配电)在一个大民族,健康维护组织集成。背景:输配电发病率据估计在只有少数研究中,代表少于120例。设计/方法:输配电病例> 300万个成员的Kaiser Permanente加州北部(KPNC) 2003 - 2007。与任何个人为肌张力障碍被确定诊断代码。一个完整的时间列表,所有医疗服务利用率为每个个人了。最终诊断分类是由两个运动障碍专家的共识,包括在可能的神经系统检查与标准化的录像数据收集。计算年平均发病率为每个肌张力障碍亚型和输配电总体而言,性别,种族和年龄群体。直接的标准化率用于2000年美国人口普查人口年龄和性别。结果:从7769年开始记录审查确认,741事件输配电资格,78%是白人。每105人年发病率是:所有输配电4.4 (95% CI 4.08, 4.72),睑痉挛1.7(1.5,1.89),颈肌张力障碍1.31(1.13,1.5),喉肌张力障碍0.81(0.67,0.94),肢体0.74 (0.6,0.85),oromandibular 0.37(0.28, 0.46),广义0.04 (0.01,0.07)。睑痉挛、颈肌张力障碍和喉肌张力障碍比男性在女性中更为常见。CONCLUSIONS: PTD incidence is estimated based on more than eleven times as many cases as the next largest study. Incidence estimates were higher for most dystonia subtypes, compared to prior estimates. Since PTD may be missed even in this equal access health care system, our estimates are likely to be conservative.Supported by: NIH 1RO1 NS046340; AHRQ RO1 HS018413; Dystonia Medical Research Foundation; Kaiser Permanente Northern California, James & Sharron Clark.Disclosure: Dr. Tanner has received personal compensation for activities with Adamas Pharmaceuticals as a consultant. Dr. Albers has nothing to disclose. Dr. Goldman has nothing to disclose. Dr. Klingman has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Marras has received personal compensation for activities with Solvay Pharmaeuticals as a consultant. Dr. Leimpeter has nothing to disclose. Dr. Fross has nothing to disclose. Dr. Gu has nothing to disclose. Dr. Smit has nothing to disclose. Dr. de Kleijn has nothing to disclose. Dr. Bhudhikanok has nothing to disclose. Dr. Ozelius has nothing to disclose. Dr. Bressman has received a royalty, liscense fee or contractual rights payment from Beth Israel/Mount Sinai/Athena. Dr. Saunders-Pullman has nothing to disclose. Dr. Comella has received personal compensation for activities with Ipsen, Merz, Allergan and NeuPathe and Medtronic as a consultant. Dr. Comella has received research support from Ipsen, Merz, Allergan, NIH, Dystonia Study Group. Dr. Nelson has received personal compensation for activities with Goldberg and Segalla. Dr. Van Den Eeden has received research support from GlaxoSmithKline, Inc.Thursday, March 21 2013, 2:00 pm-3:30 pm